Publications by authors named "A Dinoto"
Objectives: To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability.
Methods: This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (≤3 months from disease onset) and follow-up (≥6 months from the baseline), and age-matched and time to sampling-matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system.
Background: Epstein-Barr virus (EBV) infection increases the risk of having multiple sclerosis (MS). Data on adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are lacking.
Objective: To compare EBV serological status in MOGAD versus MS.
Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder.
Neurol Neuroimmunol Neuroinflamm
January 2025
Article Synopsis
- The study analyzes how often and in what way the cerebellum is affected during attacks of aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4+NMOSD), which isn't fully covered by current diagnostic standards.
- Out of 432 AQP4+NMOSD patients, 17 (4%) showed cerebellar attacks with severe neurological symptoms, including high disability scores.
- MRI results indicated that most cerebellar lesions were found in the cerebellar peduncles and dentate nucleus, with many persisting beyond six months, suggesting that understanding these patterns is important for refining future diagnostic criteria for AQP4+NMOSD.
Background And Objectives: The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis are lacking. We aimed to investigate the value of complement factors (CFs) as diagnostic and prognostic biomarkers in patients with MOGAD.
Methods: Multicentric retrospective cohort study including patients with MOGAD, multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD) with available paired serum and CSF samples.